Cholinesterase reactivators: the fate and effects in the organism poisoned with organophosphates/nerve agents.
Understanding the mechanism of action of organophosphates (OP)/nerve agents -- irreversible acetylcholinesterase (AChE, EC 3.1.1.7) inhibition at the cholinergic synapses followed by metabolic dysbalance of the organism -- two therapeutic principles for antidotal treatment are derived. The main drugs are anticholinergics that antagonize the effects of accumulated acetylcholine at the cholinergic synapses and cholinesterase reactivators (oximes) reactivating inhibited AChE. Anticonvulsants such as diazepam are also used to treat convulsions. Though there are experimental data on a good therapeutic effects of reactivators, some attempts to underestimate the role of reactivators as effective antidotes against OP poisoning have been made. Some arguments on the necessity of their administration following OP poisoning are discussed. Their distribution patterns and some metabolic and pharmacological effects are described with the aim to resolve the question on their effective use, possible repeated administration in the treatment of OP poisoning, their peripheral and central effects including questions on their penetration through the blood brain barrier as well as a possibility to achieve their effective concentration for AChE reactivation in the brain. Reactivation of cholinesterases in the peripheral and central nervous system is described and it is underlined its importance for the survival or death of the organism poisoned with OP. Metabolization and some other effects of oximes (not connected with AChE reactivation) are discussed (e.g. forming of the phosphonylated oxime, parasympatholytic action, hepatotoxicity, behavioral changes etc.). An universality of oximes able to reactivate AChE inhibited by all OP is questioned and therefore, needs of development of new oximes is underlined.
Bajgar
J
J
Department of Toxicology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
Kuca
K
K
Jun
D
D
Bartosova
L
L
Fusek
J
J
D000109:Acetylcholine / Q000032:analysis; D000931:Antidotes / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects; D002801:Cholinesterase Reactivators / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002802:Cholinesterases / Q000187:drug effects*; D003975:Diazepam / Q000627:therapeutic use; D006801:Humans; D015394:Molecular Structure; D018377:Neurotransmitter Agents / Q000493:pharmacokinetics* / Q000506:poisoning; D062025:Organophosphate Poisoning; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics*; D010091:Oximes / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D010575:Pesticides / Q000737:chemistry / Q000493:pharmacokinetics*; D012640:Seizures / Q000188:drug therapy
D000931:Antidotes; D002801:Cholinesterase Reactivators; D018377:Neurotransmitter Agents; D009943:Organophosphorus Compounds; D010091:Oximes; D010575:Pesticides; D002802:Cholinesterases; D000109:Acetylcholine; D003975:Diazepam